Element Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Element Solutions Inc

Former Louisiana AG Charles C. Foti Jr. and Kahn Swick & Foti are investigating Element Solutions Inc. (NYSE: ESI)’s proposed sale to Solstice Advanced Materials (NasdaqGS: SOLS). The deal terms call for Element shareholders to receive $10.00 in cash plus 0.500 shares of Solstice common stock for each Element share. The investigation adds uncertainty to the transaction process, but no deal economics or timeline changes were disclosed.

Analysis

This is a classic mixed-consideration arb setup, not a clean takeout. ESI holders are effectively being paid partly in a levered equity stub, so any legal chatter widens the spread through two channels: higher close-risk on ESI and lower value of the stock leg if SOLS trades down on dilution or integration concerns. The immediate winner is the event-driven desk that can isolate the cash leg; the loser is the passive ESI holder who is now long both closing risk and SOLS-specific execution risk.

The second-order dynamic is that the lawsuit inquiry can pressure SOLS more than ESI if the market concludes the deal is being reviewed because the consideration may have been too rich or the process too thin. That matters because the stock component effectively makes SOLS the financing currency; any weakness in SOLS raises the all-in cost to ESI and can force a renegotiation, especially if the combined equity trades materially below where the exchange ratio was set. Over 1-3 months, the key catalyst is whether a real fiduciary-duty challenge emerges or this stays as nuisance litigation.

Contrarian view: these investigations often compress into headline noise unless there is a broken process, but the market usually overpays for certainty on stock-for-stock deals. If SOLS is liquid enough, the better expression is a relative-value hedge rather than a naked long ESI. Falsifiers are straightforward: a clean proxy filing, no injunction motion, and SOLS holding up versus the implied deal value would argue the spread is too wide and the legal overhang is being overstated.

Key Decisions for Investors

• Conditional merger-arb: buy ESI / short SOLS in the deal ratio if the implied spread widens beyond what a routine plaintiff investigation justifies; target is spread convergence over 1-3 months, with the main risk being a real injunction or renegotiation.
• If already long ESI, hedge the stock-leg risk by shorting SOLS against the 0.5x exchange component until the proxy process clears; this reduces exposure to SOLS dilution and post-close rerating risk.
• Avoid outright directional shorts unless fresh evidence of process defects emerges; the base case is nuisance litigation, so naked bearish exposure has poor risk/reward unless the spread blows out on new facts.
• Watch for a SOLS-led move lower after any proxy or financing update; if SOLS underperforms and the implied deal value deteriorates, expect ESI downside to accelerate as arbitrageurs de-risk.